Tag Archives: USPTO

BIO’s Statement Regarding SCOTUS Patent Review Decision

lab_tech

BIO issued the following statement following yesterday’s Supreme Court decision in the case of Cuozzo Speed Technologies, LLC v. Lee. “Regrettably, today the Supreme Court missed an opportunity in the case of Cuozzo Speed Technologies, LLC v. Lee to reign in the United States Patent and Trademark Office’s Patent Trial and Appeal Board‘s invalidation of many patents under looser standards than would apply in federal court. “While we are disappointed in the Court’s ruling, it Read More >

Patently BIOtech  |  Leave a comment  |  Email This Post
Tags: , , ,

Will the PTAB Be A Roadblock for Biotech? Stories from Sessions at BIO 2016

stethoscope

We’re at the beginning of day 3 here at BIO 2016, and that means we’ve already had a full day of high quality programming for our Intellectual Property track! Let’s take a look at one of yesterday’s most popular sessions. Will the PTAB be a Road Block for Biotech? Lessons Learned from the First Three Years of Inter-Partes Review and Future Prospects Moderated by William Kubetin, Managing Editor at Bloomberg BNA Panelists: Kevin Noonan, Partner at McDonnell, Boehnen, Read More >

Patently BIOtech  |  Leave a comment  |  Email This Post
Tags: , , , , , , , , , , , , , , ,

IP Sessions at BIO 2016–Come Join us in San Francisco!

BIO CONVENTION LOGO_VERTICAL_D_CMYK

That’s right, we’re back at it again! This year’s BIO International Convention will host several innovative educational sessions on the state of intellectual property in the biotech sector.   BIO‘s top-notch education program covers the biotechnology and pharma industry’s most relevant and timely topics in intellectual property.  In each session, top thought leaders will offer insights on issues essential to the industry and provide a wealth of information of strategic relevance to the IP biotech sector.  Well, Read More >

Patently BIOtech  |  Leave a comment  |  Email This Post
Tags: , , , , , , , , , , ,

What We’ll Be Talking about at the BIO Spring IPCC Conference

IPCC Logo

It’s time once again for BIO’s Spring IPCC Conference! BIO’s biannual Intellectual Property Counsels Committee Conference provides informative and interesting educational sessions on what’s happening in the biotech IP sector. It also provides a chance to network with industry colleagues, promoting discussion and fostering new and exciting relationships. Attendees represent all swaths of the biotech sector, including pharma companies, law firms, academia and government, coming together from the U.S. and abroad to attend this one Read More >

Patently BIOtech  |  Leave a comment  |  Email This Post
Tags: , , , , , , , , , , , , , , ,

“II Ca-Be-lly, or Not II Ca-Be-lly?”: Is The Famous Cabilly II Antibody Patent Near Extinction?

N_logo_2clr

Guest post by Konstantin Linnik, Ph.D., Isaac Hubner, Ph.D, and Lana Gladstein, who are attorneys in the Boston office of Nutter McClennen & Fish LLP. On February 5, 2016, the Patent Trial and Appeal Board (“PTAB”) issued a decision to institute an Inter Partes Review (“IPR”) of Genentech’s “Cabilly II” patent (U.S. Patent No. 6,331,415). This triggered the one-month deadline for third parties to request joinder under 37 CFR § 42.122(b).  Whether you are a licensee, or otherwise Read More >

Patently BIOtech  |  Leave a comment  |  Email This Post
Tags: , , , , , , , , , , ,